Management of alcohol use disorder (AUD) is complex and is marked by a high rate of relapse. While the population of AUD patients is heterogenous, it is important to have new tools to improve their care management. This will be done by assessing innovative biomarkers to move towards precision medicine in these patients. Only a few biological collections are available to date, and the number of patients and/or samples is limited, which is why the COBIOM project was born. The objective was to create a biological collection in populations of patients with mental illness or addictive disease. In particular, the Alcohol Use Disorder axis aims to collect biological samples (blood and urine) from AUD patients hospitalized for alcohol withdrawal. The samples (serum, plasma, whole blood and urine) are managed and stored by the biological resource center INNOVABIO, and are associated with demographic, clinical, neuropsychological, nutritional, biological and imaging data. Currently more than 120 patients have been included in this collection. The scope of applications of this biological collection is very broad. This collection should make it possible to respond to clinical issues, for example by allowing the assessment of innovative markers of alcohol consumption, or the evaluation of biomarkers in the severity of alcohol withdrawal or its complications. This biological collection is available for all researchers working in the field of addiction, and interested in Alcohol Use Disorder and the improvement of patient care. Please do not hesitate to contact us if you are willing to use these samples.